Supreme Court Allows Mail-Order Mifepristone Pending Appeal

The Supreme Court has allowed the abortion pill mifepristone to remain available by mail nationwide while an appeal proceeds in a legal challenge over access to the medication.

The action keeps in place a temporary order that prevents restrictions on mifepristone from taking effect as the case continues through the courts. The medication is widely used in medication abortions and has been at the center of a closely watched lawsuit that could affect how the pill is distributed in the United States.

The court’s decision means patients will continue to be able to receive mifepristone through mail-order delivery under the status quo, at least for now. Health care providers and pharmacies that rely on mail distribution will also be able to continue operating under current rules while the litigation plays out.

The dispute has drawn national attention because it involves access to a drug used in abortion care and the reach of federal regulation of medication. A change in availability or distribution could have immediate practical effects for patients, particularly those in areas with fewer in-person providers or longer travel distances.

The Supreme Court’s move does not decide the underlying merits of the lawsuit. Instead, it pauses the impact of lower-court rulings that would have narrowed access, keeping existing access in place during the appellate process. The case is expected to continue moving forward, with additional filings and review in the lower appellate court.

What happens next will depend on the progress of the appeal and any further orders issued by the courts. The Supreme Court could be asked to take additional action later, including whether to weigh in more directly on the legal questions presented.

For now, the court’s order preserves the current national availability of mifepristone by mail as the legal fight over the drug continues.